Page 18 - Eva Kalias News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Santhera Pharmaceuticals Holding AG: Santhera gibt den Vollzug des Umtauschangebots für die Wandelanleihe per 4. Mai 2021 bekannt Pratteln, Schweiz, 3. März 2021 angekündigte Umtauschangebot für die CHF 60 Millionen Wandelanleihe am 4. Mai 2021 vollzogen wird. Mit dem Rückkaufsinserat vom 25. März 2021 (das Rückkaufsinserat) veröffentlichte Santhera Pharmaceuticals Holding AG ein Angebot zum Umtausch der ausstehenden CHF 60 Millionen 5%-Wandelanleihe mit Fälligkeit 2022 (die 2017/22 Wandelanleihe) nach den im Rückkaufsinserat aufgeführten Konditionen (das Umtauschangebot). Das U...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Santhera Completes Capital Increases for Financing Arrangements Santhera Pharmaceuticals Holding AGApril 30, 2021 GMT Pratteln, Switzerland, April 30, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,312,000 treasury shares. On April 30, 2021, Santhera completed the ordinary capital increase resolved on March 18, 2021, by issuing 312,000 new treasury shares for purposes of the planned restructuring of the CHF 60 million convertible bond 2017-2022 (ISIN CH0353955195) ...

Santhera Pharmaceuticals Holding AG: Santhera Completes Capital Increases for Financing Arrangements 2, shares. On April 30, 2021, Santhera completed the ordinary capital increase resolved on March 18, 2021, by issuing 312,000 new treasury shares for purposes of the planned restructuring of the CHF 60 million convertible bond 2017-2022 (ISIN CH0353955195) and potentially for other purposes. At the same time, 2,000,000 shares were issued out of the existing authorized capital as treasury shares. The newly created registered shares will initially be held as treasury shares in order to fulfill ...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

Santhera Pharmaceuticals Holding AG: Santhera Reports 2020 Annual Results 4 this statement. CHF 67.7 20 as the basis for future growth S Pratteln, Switzerland, Company 20 lead uchenne muscular dystrophy (D . "Santhera started 2021 with the strong foundation of a refreshed clinical and operational strategy focused on vamorolone, which we believe can provide significant value to patients, caregivers, and ultimately shareholders. It represents the key foundation for the future of Santhera, which continues to focus on Duchenne muscular dystrophy (DMD) and other rare diseases.," said Dario E...